Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

The purpose of this trials is to investigate what proteins and genes are related to the recurrence of colorectal cancer.

The aim is to identify potential biomarkers in plasma and tissue which can predict:

– Early recurrence of colorectal cancer and

– Presence of tumour deposits after completion of chemotherapy.

Once discovered, the most accurate and sensitive combination of predictive biomarkers can be applied in routine clinical use.

Patient Profile

All patients with suspected to have stage 2/3 colorectal cancer and are planned to have surgical treatment.

  1. Patients will be asked to donate blood samples at various time points before and during their treatment and once every 3 months post-treatment for up to 2 years, depending on the path of their disease. These blood samples will be taken at time of normal blood work.
  2. Allow access to fixed tumour tissue blocks, which had been developed from tissue taken during the standard surgery.

Where’s this trial being run?

Beacon Hospital, Beaumont Hospital, Bon Secours Cork, Letterkenny University Hospital, Sligo University Hospital, St James’s Hospital, Tallaght University Hospital, St Vincents University Hospital, University Hospital Galway, University Hospital Waterford, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: CRAC Plasma Biomarker
Number: 12-27
Full Title:

Identification of Plasma Biomarkers in Early Detection of Colorectal Adenocarcinoma
Recurrence (CRAC Plasma Biomarker Study).

Principal Investigator: Prof Ray McDermott (Tallaght Hospital)
Type: In-House
Sponsor:

Cancer Trials Ireland.

Recruitment Started: Global: Not Applicable
Ireland: April 2014
Global Recruitment Target: Not Applicable
Ireland Recruitment Target: 130